Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expressions of C/EBPα and PPAR-γ were both negatively related with FOXC1 in human HCC tissue.
|
31512996 |
2020 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-κB-TAK1-ERK1/2 axis in the context of PPARγ agonistic activity.
|
31367864 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatic peroxisome proliferator-activated receptor γ coactivator 1β drives mitochondrial and anabolic signatures that contribute to hepatocellular carcinoma progression in mice.
|
28857232 |
2018 |
Liver carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, alteration of PPAR-γ or AKT phosphorylation could reverse the function of miR-1468 in HCC.
|
29510736 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that PPARγ activation by hispidulin effectively suppressed HCC cell growth and metastasis both in vitro and in vivo.
|
29656183 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our previous studies indicated that combination of Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and PPARγ ligand Troglitazone (TZD), can induce significant apoptosis in various TRAIL-resistant prostate and hepatocellular carcinoma (HCC) cells.
|
29615720 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our results support the notion that PPARγ ligands can inhibit the proliferation of hepatocellular carcinoma cells in a time- and dose-dependent manner, and that this is at least in part due to the resulting upregulation of PTEN expression.
|
28943966 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inflammatory (TNF, LPS, IL-6) and profibrotic mediators (TGF-beta) do not regulate TUBA8 in HepG2 cells, primary HSC and the HSC cell line LX-2, when stimulated for 24 h. Agonists of the farnesoid X receptor and peroxisome proliferator activated receptor gamma, which are nuclear receptors involved in NASH and HCC pathophysiology, have no effect on TUBA8 in HepG2 and LX-2 cells.
|
28063004 |
2017 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It was also be found that ONTD increase the PPAR-γ activity, reduce the phosphorylation of Akt and increase phosphatase and tensin homologue (PTEN) protein expression in hepatocellular carcinoma (HCC) Bel-7402 cells, and these were associated with the inhibition of cells proliferation.
|
28834734 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARγ contributes to the suppression of HCC cell growth, migration, and angiogenesis.
|
27483249 |
2016 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, the effects of SEPT2 on the above factors could be suppressed by PPARγ overexpression, suggesting that PPARγ could inhibit HCC cell growth via regulating the expression and blocking the oncogenic function of SEPT2.
|
25592041 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene peroxisome proliferator-activated receptor γ.
|
25836616 |
2015 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR-γ) was inversely correlated with miR-130b expression in HCC tissues.
|
25387077 |
2014 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study suggests that celecoxib suppresses cancer stemness and progression of HCC via activation of PPARγ/PTEN signaling.
|
24721996 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study provides important evidence for inhibition of hepatocellular carcinoma (HCC) growth by 15-PGDH through the 15-keto-prostaglandin E2 (15-keto-PGE2)/peroxisome proliferator-activated receptor-γ (PPARγ)/p21(WAF1/Cip1) signaling pathway.
|
23542179 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells.
|
23703729 |
2013 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma.
|
23640460 |
2013 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, the present study demonstrated that both ERα and β were sufficient to inhibit PPARγ and provide a valuable therapeutic option for the treatment of HCC patients.
|
24126791 |
2013 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Alocasia macrorrhiza extract has potential cytotoxic and apoptotic effect on human hepatocellular carcinoma cells and inhibits hepatoma growth in vivo, its mechanism of action might be associated with the inhibition of DNA synthesis, cell cycle (G(0)/G(1)) arrest, apoptosis induction through up-regulation the mRNA and protein expressions of PPARγ, Rb, Bax and capase-3genes and down-regulation of the expressions of Cyclin D1 and Bcl-2 genes.
|
22472110 |
2012 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-gamma exerts an inhibitory effect on the invasive and metastatic potential of HCC in vitro and in vivo, and is thus, a target for the prevention and treatment of HCC metastases.
|
22472882 |
2012 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although peroxisome proliferator-activated receptor gamma (PPARgamma) agonist have been shown to inhibit hepatocellular carcinoma (HCC) development, the role of PPARgamma in hepatocarcinogenesis remains unclear.
|
20512989 |
2010 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, a group of 60 follicular thyroid neoplasms [18 FTC, 1 Hurthle cell carcinoma (HCC), 24 follicular thyroid adenomas (FTA), 5 Hurthle cell adenomas (HCA), and 12 follicular variants of papillary thyroid carcinomas (FV-PTC)] were analyzed to determine the prevalence of the PAX8-PPARG translocation by fluorescence in situ hybridization.
|
19963130 |
2010 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the effects of rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on the expression of the phosphatase and tensin homologue deleted on chromosome 10 gene (PTEN) and cell growth in hepatocellular carcinoma cells, as well as the underlying mechanisms of these effects.
|
17506947 |
2007 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined the effects of PPARgamma activation by troglitazone on hepatocellular carcinoma (HCC) cell growth, proliferation, and apoptosis in vitro and in vivo.
|
16374840 |
2006 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since a crosstalk between AGE and angiotensin II (Ang II) has been proposed in the pathogenesis of accelerated atherosclerosis in diabetes, we examined here whether and how telmisartan, a unique Ang II type 1 receptor blocker (ARB) with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity, could inhibit AGE-induced CRP expression in a human hepatoma cell line, Hep3B cells.
|
17004092 |
2006 |